Wegovy Tablets Vs Injections

If you have been searching for a medically proven way to lose weight and keep it off, you have probably already come across the name Wegovy. It has been one of the most talked-about weight loss treatments in the UK since its launch, and for very good reason. But with so much noise online — half of it hype, half of it misinformation — it can be genuinely difficult to separate fact from fiction. This guide cuts through all of that. Whether you are wondering whether Wegovy tablets exist, how the injectable version works, what side effects to expect, or how to access it safely through a UK prescriber in 2026, you will find clear, honest, clinically accurate answers right here.

Quick Summary

Wegovy (semaglutide 2.4 mg) is a once-weekly injectable prescription treatment licensed in the UK for chronic weight management in adults with obesity or overweight with at least one weight-related health condition. It works by mimicking a natural gut hormone that reduces appetite, slows gastric emptying, and helps you feel full for longer — leading to clinically significant, sustained weight loss when combined with a reduced-calorie diet and exercise.

• Wegovy is a GLP-1 receptor agonist containing semaglutide, administered via a pre-filled pen injection once weekly
• There are currently no licensed Wegovy tablets — the treatment is injectable only, though oral semaglutide research is ongoing
• Clinical trials show average weight loss of around 15% of body weight over 68 weeks
• The dose is gradually increased from 0.25 mg to the 2.4 mg maintenance dose over 16 weeks to reduce side effects
• It must be prescribed by a qualified UK prescriber after a clinical assessment — it is not available over the counter

Table of Contents

1. What Is Wegovy and Does It Come as a Tablet?
2. How Wegovy Works to Reduce Body Weight
3. Wegovy Dosing Schedule: From Start to Maintenance
4. Who Is Eligible for Wegovy in the UK?
5. Managing Side Effects and Getting the Most from Treatment
6. Wegovy vs Other Weight Loss Treatments Available in the UK
7. Key Takeaways
8. When to Seek Professional Advice
9. Scientific References
10. FAQs

What Is Wegovy and Does It Come as a Tablet?

This is one of the most common questions people type into search engines: are there Wegovy tablets? The honest answer is no — not in the UK, and not yet anywhere as a licensed weight loss product. Wegovy is the brand name for semaglutide 2.4 mg, and it is currently only available as a subcutaneous injection delivered via a pre-filled, disposable pen device. The injection is self-administered once weekly into the abdomen, thigh, or upper arm.

Semaglutide does exist in oral tablet form under a different brand — Rybelsus — but that product is licensed specifically for type 2 diabetes management, not weight loss, and the dose is significantly lower. So when people search for Wegovy tablets, they are often hoping for a pill-based alternative to the injections. While it is understandable to want one, it is important to be clear: the licensed treatment for weight management using semaglutide remains injectable only in the UK as of 2026.

Wegovy was approved by the MHRA (Medicines and Healthcare products Regulatory Agency) for use in the UK and has since become one of the most prescribed obesity treatments available through both NHS specialist services and private online prescribers. The pen device is designed to be intuitive and nearly painless, using a very fine needle, and most people find the weekly injection far less daunting than they initially expected.

• Wegovy contains semaglutide at a 2.4 mg maintenance dose — higher than any diabetes formulation
• It is supplied as a pre-filled injection pen, not a tablet or capsule
• Oral semaglutide (Rybelsus) is licensed only for type 2 diabetes at lower doses
• Research into higher-dose oral semaglutide for obesity is ongoing but not yet licensed in the UK
• All legitimate supplies of Wegovy in the UK require a valid prescription from a registered prescriber

How Wegovy Works to Reduce Body Weight

Understanding how Wegovy works can make a real difference to how you approach treatment — and it helps explain why the results are so much more impressive than many traditional approaches to weight loss. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone your gut naturally produces after you eat. It signals to your brain that you are full, slows the rate at which your stomach empties, and reduces the overall desire to eat. Wegovy mimics and amplifies this signal, keeping it active for far longer than the natural version.

The result is that people on Wegovy experience a genuine and sustained reduction in appetite. They feel fuller sooner, stay full longer, and find that cravings — particularly for high-calorie, ultra-processed foods — diminish noticeably. This is not a willpower story. The medication is working directly on the brain's appetite regulation centres, particularly in the hypothalamus. It changes the way hunger feels at a biological level, which is why many patients describe treatment as finally feeling in control of their eating for the first time.

Beyond appetite, semaglutide also has beneficial effects on blood glucose regulation, which is part of why it was originally developed for type 2 diabetes. For people with obesity and insulin resistance, these metabolic improvements are an important secondary benefit of treatment. The STEP clinical trial programme, which ran across thousands of participants, consistently showed that Wegovy produced weight loss of between 10% and 17% of body weight depending on the population studied — far exceeding results seen with lifestyle interventions alone.

• GLP-1 receptor agonists mimic a natural satiety hormone your gut already produces
• Semaglutide slows gastric emptying, meaning food stays in your stomach longer
• It acts on appetite-regulating centres in the brain to reduce hunger and cravings
• Blood glucose regulation improves, which benefits those with pre-diabetes or type 2 diabetes
• The STEP 1 trial showed an average weight reduction of 14.9% of body weight over 68 weeks

Wegovy Dosing Schedule: From Start to Maintenance

One of the biggest pain points people face when starting Wegovy is not knowing what to expect from the dosing process, and worrying about side effects if the dose is increased too quickly. The good news is that Wegovy uses a carefully designed escalation schedule specifically designed to minimise gastrointestinal side effects while your body adjusts to the medication. This step-up approach is a key part of why most people tolerate the treatment well.

You begin at the lowest dose — 0.25 mg once weekly — for the first four weeks. This is not a therapeutic dose for weight loss; it is purely an introductory dose to acclimatise your digestive system. After four weeks, the dose increases to 0.5 mg for another four weeks, then 1 mg, then 1.7 mg, and finally the full maintenance dose of 2.4 mg weekly is reached at week 17 onwards. Each step lasts four weeks, and you should not rush the escalation even if you feel you are tolerating it well. Your prescriber can advise on whether to pause the escalation at any step if side effects are difficult to manage.

Many people find that their weight loss really accelerates once they reach the 1.7 mg and 2.4 mg doses, so patience with the escalation phase is genuinely worthwhile. It is also worth noting that missing an injection is not cause for alarm — if you miss a dose and your next scheduled dose is more than two days away, you can take it as soon as you remember and then resume your normal schedule. If it is less than two days until your next dose, simply skip the missed one and carry on.

Week	Dose	Purpose	What to Expect
Weeks 1–4	0.25 mg weekly	Initiation / tolerability	Mild nausea possible; appetite changes may begin
Weeks 5–8	0.5 mg weekly	Dose escalation	Appetite reduction more noticeable; some GI symptoms
Weeks 9–12	1 mg weekly	Dose escalation	Steady weight loss begins; fatigue may ease
Weeks 13–16	1.7 mg weekly	Dose escalation	Significant appetite suppression; weight loss accelerates
Week 17 onwards	2.4 mg weekly	Maintenance dose	Maximum therapeutic effect; sustained weight loss

• Never skip the escalation phase — it significantly reduces the risk of nausea and vomiting
• Each dose is delivered via the same pre-filled pen format, just at a different strength
• Store pens in the fridge (2–8°C) before first use; they can be kept at room temperature for up to 28 days after first use
• Always inject into a different area each week to avoid skin irritation at the injection site

Who Is Eligible for Wegovy in the UK?

Not everyone who wants to lose weight will qualify for Wegovy, and understanding the eligibility criteria upfront saves you time and helps you approach your consultation prepared. In the UK, Wegovy is licensed for adults who have a body mass index (BMI) of 30 or above (classified as obese), or a BMI of 27 or above with at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnoea, or cardiovascular disease. This reflects its licence as a treatment for a medical condition — obesity — rather than cosmetic weight loss.

Wegovy is not suitable for everyone, however. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). It should be used with caution in people with a history of pancreatitis, diabetic retinopathy, or severe gastrointestinal conditions. It is not recommended during pregnancy or breastfeeding. A full clinical assessment — which a good prescriber will always carry out — screens for all of these contraindications.

It is also worth addressing a common frustration: accessing Wegovy through the NHS has been slow and inconsistent, with specialist weight management services overwhelmed in many parts of the UK. This is why many people are turning to reputable private online pharmacy services with registered prescribers, where a consultation can be completed online and treatment dispatched discreetly. If you are considering this route, always verify that the pharmacy is registered with the GPhC (General Pharmaceutical Council) and that prescriptions are issued by a UK-registered prescriber — not generated automatically or imported from abroad.

• BMI of 30+ (obese) or BMI 27+ with a weight-related health condition qualifies most adults
• A clinical assessment must screen for contraindications before prescribing
• NHS access is limited; private prescribers offer a compliant alternative for many patients
• Pregnant or breastfeeding women should not use Wegovy
• Always verify GPhC registration before purchasing from any online pharmacy

Managing Side Effects and Getting the Most from Treatment

Side effects are the number one reason people consider stopping Wegovy early — and that is a genuine shame, because the vast majority of side effects are temporary, dose-dependent, and very manageable with the right approach. Understanding what to expect and having simple strategies ready makes an enormous difference to your ability to stay on treatment and achieve meaningful, lasting weight loss.

The most commonly reported side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These are most pronounced during the dose escalation phase and typically reduce significantly once you reach your maintenance dose and your body has fully adjusted. Eating smaller meals, avoiding fatty or spicy foods, staying well hydrated, and not lying down immediately after eating all help considerably. If nausea is severe, speak to your prescriber — there is no need to push through without support.

Some people experience fatigue, headaches, or dizziness in the early weeks, particularly around the time of their weekly injection. These usually settle with time. A small number of people report injection site reactions — redness, itching, or a small lump at the injection site — which can be minimised by rotating the injection location each week. If you experience more serious symptoms such as severe abdominal pain radiating to the back (which could indicate pancreatitis), vision changes, a rapid heartbeat, or signs of a severe allergic reaction, stop the medication and seek immediate medical attention.

One practical pain point worth addressing is the so-called "Wegovy plateau" — a period where weight loss slows or temporarily stalls, which many people experience around months three to five of treatment. This is a normal physiological response, not treatment failure. Reviewing your diet, increasing physical activity, and speaking to your prescriber about your progress can help push through this phase. Combining Wegovy with evidence-based behavioural support significantly improves long-term outcomes.

• Nausea is the most common side effect and typically peaks during dose escalation before improving
• Eat smaller, lower-fat meals and stay hydrated to manage gastrointestinal symptoms
• Rotate injection sites weekly to reduce local skin reactions
• Weight loss plateaus are normal and do not mean the medication has stopped working
• Seek urgent medical advice if you experience severe abdominal pain, vision changes, or signs of allergic reaction

Wegovy vs Other Weight Loss Treatments Available in the UK

If you are weighing up your options, it helps to understand how Wegovy compares to the other weight loss treatments that are legitimately available in the UK. The landscape has changed considerably in recent years, with several new prescription treatments alongside long-established options, and each has a different mechanism, efficacy profile, and suitability depending on your health history.

Mounjaro (tirzepatide) is perhaps the most direct comparator to Wegovy. It is a dual GIP and GLP-1 receptor agonist, meaning it activates two hormone pathways rather than one, and clinical trials have shown average weight loss of up to 22.5% of body weight — substantially higher than Wegovy in head-to-head data. It is now available in the UK through private prescribers and is also being rolled out via NHS specialist pathways. For many patients with higher BMIs or those who have not responded sufficiently to semaglutide, tirzepatide represents a compelling next step.

Orlistat (available as Orlos) is a well-established over-the-counter option that works by blocking the absorption of dietary fat in the gut. It is less effective than Wegovy — producing average weight loss of around 5–7% of body weight — and it comes with well-known side effects including oily stools and fatty discharge if dietary fat intake is not carefully controlled. It is suitable for people who are not eligible for or who prefer not to use injectable treatments. XLS Medical Weight Loss Plus is a non-prescription supplement that helps reduce the absorption of calories from dietary fat and carbohydrates, and while it is not comparable to prescription options in terms of clinical evidence, it can support a structured weight loss programme for those with lower BMIs.

For completeness, it is worth noting that XLS Medical Direct Fat Binder is another non-prescription option that works by physically binding to dietary fat in the stomach, reducing the amount absorbed. Again, this is a supplementary aid rather than a replacement for medical treatment in those who qualify for prescription therapy. The key takeaway from comparing these options is that for people who meet the clinical criteria, Wegovy and Mounjaro offer by far the strongest evidence base for clinically meaningful, sustained weight loss.

Treatment	Type	Average Weight Loss	Prescription Required	Best For
Wegovy (semaglutide)	GLP-1 injection	~15% body weight	Yes	BMI 30+ or 27+ with comorbidity
Mounjaro (tirzepatide)	GLP-1 / GIP injection	~20–22% body weight	Yes	Higher BMI, stronger effect needed
Orlistat (Orlos)	Fat absorption blocker	~5–7% body weight	OTC / Prescription	Low-to-moderate BMI, non-injectable preference
XLS Medical Plus	OTC supplement	~3–5% body weight	No	Mild excess weight, lifestyle support
XLS Medical Fat Binder	OTC supplement	~3–4% body weight	No	Supplementary support alongside diet

• Wegovy offers the best-evidenced injectable option specifically licensed for weight management at its 2.4 mg dose
• Mounjaro achieves greater average weight loss but may not be suitable for everyone
• Orlistat is effective for those who cannot or choose not to use injections
• Non-prescription supplements have a role in mild cases but are not comparable to licensed medicines
• Your prescriber is best placed to recommend the most appropriate treatment for your individual circumstances

Key Takeaways

• Wegovy tablets do not currently exist as a licensed product in the UK — the treatment is an injectable semaglutide pen used once weekly
• Wegovy works by mimicking the GLP-1 gut hormone to reduce appetite, slow gastric emptying, and regulate blood glucose — producing average weight loss of around 15% over 68 weeks
• The dose is escalated slowly over 16 weeks from 0.25 mg to the 2.4 mg maintenance dose to minimise gastrointestinal side effects
• Eligibility requires a BMI of 30+ or 27+ with a weight-related health condition, and a clinical assessment by a registered UK prescriber
• Private online prescribers offer a legitimate, GPhC-regulated route to accessing Wegovy tablets and other weight loss treatments when NHS access is limited

When to Seek Professional Advice

While Wegovy is a safe and effective treatment for the vast majority of eligible people, there are specific situations where you should speak to a healthcare professional promptly rather than waiting for your next scheduled review. Knowing when to act is an important part of managing your treatment responsibly.

Contact your prescriber or GP if you experience persistent, severe nausea or vomiting that prevents you from eating or drinking adequately. If you develop severe abdominal pain — especially pain that radiates to your back — this may indicate pancreatitis and requires immediate medical assessment. Any unexplained lump in your neck, difficulty swallowing, or hoarseness could suggest thyroid involvement and warrants urgent review. If you are taking medications for type 2 diabetes alongside Wegovy, your blood glucose should be closely monitored as your diabetes medication doses may need reducing. Signs of low blood sugar — shakiness, sweating, confusion — also need prompt attention.

More broadly, if you reach your maintenance dose and find that weight loss has stopped entirely for more than three months despite good adherence to the treatment and lifestyle recommendations, it is worth discussing with your prescriber whether your treatment plan should be reviewed or whether a different approach — such as switching to Mounjaro tirzepatide injections — may be more appropriate for your needs.

• Severe or persistent vomiting preventing adequate hydration — contact your prescriber
• Severe abdominal pain radiating to the back — seek emergency assessment immediately
• New neck lump, hoarseness, or difficulty swallowing — urgent GP review needed
• Symptoms of hypoglycaemia if taking diabetes medication concurrently — contact your care team
• Complete weight loss plateau after three months at maintenance dose — request a treatment review

Scientific References

1. Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 Trial). New England Journal of Medicine, 384(11), 989–1002.
2. National Institute for Health and Care Excellence (NICE). (2023). Semaglutide for managing overweight and obesity. NICE Technology Appraisal Guidance TA875.
3. Medicines and Healthcare products Regulatory Agency (MHRA). (2022). Regulatory approval of Wegovy (semaglutide). MHRA, UK Government.

Frequently Asked Questions

How long does Wegovy take to start working for weight loss?

Wegovy typically begins to produce noticeable weight loss results within the first four to eight weeks of treatment, though the most significant reductions are usually seen after three to six months at the full maintenance dose. Clinical trials show an average body weight reduction of around 15% over 68 weeks with consistent use alongside lifestyle changes.

Is Wegovy safe to use long term in the UK?

Wegovy is considered safe for long-term use when prescribed and monitored by a qualified UK prescriber. It is licensed by the MHRA and has been studied in trials lasting over 68 weeks. Regular reviews with your prescriber help manage any side effects and ensure the treatment continues to be appropriate for your health needs.

Can you take Wegovy with other weight loss treatments?

Wegovy should not routinely be combined with other prescription weight loss medications without specific medical guidance. However, lifestyle interventions such as a reduced-calorie diet and increased physical activity are always recommended alongside it. Your prescriber will review your full medication list to check for interactions before starting treatment.

What is the starting dose of Wegovy for weight management?

The starting dose of Wegovy is 0.25 mg once weekly by subcutaneous injection, maintained for the first four weeks to allow your body to adjust. The dose is then gradually increased every four weeks — through 0.5 mg, 1 mg, and 1.7 mg — until reaching the full maintenance dose of 2.4 mg once weekly.